GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhejiang East Asia Pharmaceutical Co 605177.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

19.41

-4.10%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Zhejiang East Asia Pharmaceutical Co

Its shares trade on Shanghai under the ticker 605177.SS. It has been listed since 25 November 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥940.2m and a net loss of CN¥82.4m. At that date it held total assets of CN¥3.34bn and shareholders' equity of CN¥1.81bn.

Zhejiang East Asia Pharmaceutical Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Taizhou, Zhejiang. The company went IPO on 2020-11-25. Zhejiang East Asia Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of chemical raw medicine and pharmaceutical intermediates. The firm's products mainly cover antibacterial drugs (including β-lactams and quinolones), anticholinergic and synthetic antispasmodic drugs (including trimebutine maleate) and antifungal drugs for skin. The firm's anticholinergic and synthetic antispasmodics are mainly used to treat gastrointestinal smooth muscle spasm and functional gastrointestinal diseases. The firm distributes its products in domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
25 Nov 2020
Employees
1,749
Website
eapharm.net ↗

Leadership

Pay as last reported

  • Mr. Cheng ChiChairman of the Board, General Manager, since 2015
  • Ms. Xiaomin WangFinance Director
  • Mr. Daomin XiaDeputy General Manager, Director, since 2015
  • Ms. Lingzhi ChenDeputy General Manager
  • Mr. Jianbo ZhouSecretary of the Board
  • Mr. Jiangli QianDirector
  • Mr. Sheng WangDirector
  • Mr. Sunliang CuiIndependent Director
  • Ms. Yan FengIndependent Director
  • Mr. Fangzhong QiIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company is headquartered in Taizhou, Zhejiang with 1,749 employees.
  • Operates in Pharmaceuticals industry with focus on R&D, production, and sales.
  • Products include antibacterial, anticholinergic, and antifungal drugs for skin.

Weaknesses

  • Company went public on 2020-11-25, indicating relatively recent IPO.
  • Relies on domestic and overseas markets for product distribution.
  • No specific financial metrics provided for performance evaluation.

Opportunities

  • Expansion in domestic market for pharmaceutical products.
  • Growth potential in overseas markets for chemical raw medicine.
  • Focus on R&D could lead to new product development.

Threats

  • Competition in Pharmaceuticals industry may impact market share.
  • Dependence on specific product categories like antibacterial drugs.
  • Untrusted source description may affect reliability of information.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.